PAMELA MCELEARNEY: Open Payments
NPI 1740234681 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,876 in 92 payments from 19 companies in 2025. Trend: 2023 $1,178 · 2024 $1,806 · 2025 $1,876
Food & beverage: $1,876
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 11 | $383 |
| Novartis Pharmaceuticals Corporation | 13 | $258 |
| UCB, Inc. | 14 | $244 |
| ABBVIE INC. | 14 | $189 |
| Janssen Biotech, Inc. | 5 | $99 |
| LEO Pharma Inc. | 4 | $85 |
| Arcutis Biotherapeutics, Inc. | 1 | $81 |
| Galderma Laboratories, L.P. | 4 | $78 |
| Organon LLC | 6 | $66 |
| MAYNE PHARMA COMMERCIAL LLC | 4 | $64 |
Products named: DUPIXENT, Bimzelx, COSENTYX, RINVOQ, TREMFYA, Zoryve, NEMLUVIO, ADBRY.
Industry payments across GA — which companies pay providers there.
